id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S16219 R67858 |
Ahlqvist (Population-Based), 2024 | Autism - ICD-10 (F84) or ICD-9 (299) - Median (IQR) follow-up of 13.4 (7.6-19.8) years | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy | 1.05 [1.02;1.08] | 5,912/185,909 62,672/2,294,888 | 68,584 | 185,909 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16218 R67859 |
Ahlqvist (Sibling), 2024 | Autism - ICD-10 (F84) or ICD-9 (299) - Median (IQR) follow-up of 13.4 (7.6-19.8) years | during pregnancy (anytime or not specified) | population based cohort retrospective | sibling excluded | Adjustment: Yes Control group: Sibling Paracetamol use: maternal ITW/questionnaires during pregnancy |
0.98 [0.93;1.04] excluded (control group) |
3,956/- 41,294/- | 45,250 | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16316 R67860 |
Liew b, 2016 | Autism Spectrum Disorder diagnosis (ICD-10 F84.0-F84.9) - Follow-up 11-17 years old (average 12.7 years) | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes Paracetamol use: maternal ITW/questionnaires during pregnancy | 1.19 [1.04;1.35] | 626/36,187 401/28,135 | 1,027 | 36,187 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 1.10 [0.98;1.24] | 69,611 | 222,096 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Population-Based;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 16218